AM-1346

AM-1346 is a synthetic cannabinoid that acts as a potent and selective agonist for the cannabinoid receptor CB1, with a Ki value of 1.5 nM. It is a member of the AM series of cannabinoids, which were developed by the research group led by Alexandros Makriyannis.

Chemical Structure and Properties

AM-1346 is a derivative of the classical cannabinoid structure, featuring a dibenzopyran ring system. The compound is characterized by the presence of a 1,1-dimethylheptyl side chain, which is known to enhance the binding affinity and potency of cannabinoids at the CB1 receptor. The stereochemistry of AM-1346 is defined by its (6aR,10aR) configuration, which is crucial for its activity.

Pharmacology

AM-1346 is a full agonist at the CB1 receptor, which is primarily located in the central nervous system. Activation of CB1 receptors by AM-1346 leads to a variety of effects, including analgesia, appetite stimulation, and modulation of mood and cognition. The compound's high affinity and selectivity for CB1 make it a valuable tool for studying the physiological and pathological roles of this receptor.

Metabolism

The metabolism of AM-1346 is primarily hepatic, involving cytochrome P450 enzymes. The metabolic pathways include hydroxylation and oxidation, leading to the formation of various metabolites that are excreted via the renal route.

Research and Applications

AM-1346 is used in scientific research to explore the endocannabinoid system and its potential therapeutic targets. Studies have investigated its effects on pain modulation, neuroprotection, and appetite regulation. However, due to its potent psychoactive effects, AM-1346 is not approved for medical use in humans.

Legal Status

As a synthetic cannabinoid, AM-1346 is classified as a research chemical and is not approved for human consumption. Its legal status varies by country, with some jurisdictions placing it under controlled substance regulations due to its potential for abuse and psychoactive effects.

Safety and Toxicology

The safety profile of AM-1346 has not been extensively studied in humans. In animal models, high doses of AM-1346 can lead to typical cannabinoid effects such as hypothermia, catalepsy, and reduced locomotor activity. Long-term effects and potential toxicity remain areas of active research.

Also see

• Cannabinoid receptor
• Synthetic cannabinoids
• Endocannabinoid system
• AM series